UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Clinical cancer research, 2013-03, Vol.19 (5), p.1021-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

Clinical cancer research, 2013-10, Vol.19 (19), p.5542-5542

2013

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of Melanoma: Facts and Hopes

Clinical cancer research, 2019-09, Vol.25 (17), p.5191-5201

2019

Link zum Volltext

Verfügbarkeit prüfen

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

The Journal of clinical investigation, 2018-02, Vol.128 (2), p.715-720

2018

Link zum Volltext

Verfügbarkeit prüfen

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Nature medicine, 2022-02, Vol.28 (2), p.353-362

2022

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

Journal of clinical oncology, 2016-03, Vol.34 (8), p.833-842

2016

Link zum Volltext

Verfügbarkeit prüfen

Programmed death ligand-1 expression in non-small cell lung cancer

Laboratory investigation, 2014-01, Vol.94 (1), p.107-116

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-09, Vol.23 (18), p.5349-5357

2017

Link zum Volltext

Verfügbarkeit prüfen

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Clinical cancer research, 2017-04, Vol.23 (8), p.1929-1936

2017

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nature communications, 2016-08, Vol.7 (1), p.12624-12624, Article 12624

2016

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Ipilimumab in Advanced Melanoma

The New England journal of medicine, 2013-07, Vol.369 (2), p.122-133

2013

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The lancet oncology, 2015-04, Vol.16 (4), p.375-384

2015

Link zum Volltext

Verfügbarkeit prüfen

Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications

Journal for immunotherapy of cancer, 2023-01, Vol.11 (1), p.e006346

2023

Link zum Volltext

Verfügbarkeit prüfen

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

Nature genetics, 2015-09, Vol.47 (9), p.996-1002

2015

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Clinical cancer research, 2017-08, Vol.23 (15), p.4270-4279

2017

Link zum Volltext

Verfügbarkeit prüfen

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Nature communications, 2022-02, Vol.13 (1), p.898-898, Article 898

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical cancer research, 2016-11, Vol.22 (22), p.5461-5471

2016

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

The lancet oncology, 2012-05, Vol.13 (5), p.459-465

2012

Link zum Volltext

Verfügbarkeit prüfen

Release the Hounds! Activating the T-Cell Response to Cancer

The New England journal of medicine, 2015-01, Vol.372 (4), p.374-375

2015

Link zum Volltext

Verfügbarkeit prüfen

Cancer Immunotherapy: Past Progress and Future Directions

Seminars in oncology, 2015-08, Vol.42 (4), p.518-522

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Journal of clinical oncology, 2018-04, Vol.36 (10), p.1020-1044

2018

Link zum Volltext

Verfügbarkeit prüfen

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2914-2925

2021

Link zum Volltext

Verfügbarkeit prüfen

TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions

Clinical cancer research, 2021-10, Vol.27 (19), p.5156-5157

Sznol, Mario

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 333

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(318)
Mit Volltextzugriff
(304)

Publikationsform

Artikel
(327)
Reviews
(2)
Texte
(2)
Buchkapitel
(1)
Berichte
(1)

Sprache

Englisch
(333)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

Immunotherapy of Melanoma: Facts and Hopes

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Programmed death ligand-1 expression in non-small cell lung cancer

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nivolumab plus Ipilimumab in Advanced Melanoma

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Release the Hounds! Activating the T-Cell Response to Cancer

Cancer Immunotherapy: Past Progress and Future Directions

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions

Suchergebnisse filtern